The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Pitroda, Sean
PropertyValue
overview My long-term vision is to improve the treatment of metastatic disease through translational research. I believe this can only be achieved through challenging the prevailing view that metastases are always widespread and incurable. My laboratory utilizes integrative molecular analyses of clinical metastases, bioinformatics and computational tools, tumor models, molecular biology, immunologic analyses, and statistical modeling to investigate: (1) biological mechanisms that restrict the potential curability of patients with limited metastatic disease following localized therapies, such as surgery and ablative radiotherapy, and (2) the interplay between ablative radiotherapy and immune checkpoint blockade in patients with metastatic disease. We discovered the first biological basis for curable metastasis in patients with colorectal cancer who underwent surgical resection of limited de novo liver metastases, whereby robust adaptive immune activation in concert with favorable clinical factors was associated with a 10-year overall survival of ~95% following surgery (Nature Communications 2018). We recently validated these findings in the randomized phase III New EPOC trial (JAMA Oncology 2023). In addition, we discovered that concurrent administration of ablative radiotherapy with immunotherapy augmented local tumor immunity and improved survival in patients with highly aneuploid metastatic non-small cell lung cancer (NSCLC) (Nature Cancer 2022). We validated a tumor aneuploidy score as a novel biomarker of immunotherapy response across multiple human cancers (Nature Genetics 2022). Building upon these findings, we identified previously unknown mechanisms of immune suppression and novel strategies to augment the diminished immune responses in metastatic cancers. I anticipate these findings will ultimately have important implications in the delineation of those patients with potentially curable metastatic disease from those whose few metastases are part of a large cascade of widespread disease, thereby advancing the paradigm for the treatment of metastatic cancers. My technical expertise and clinical oncology training combined with my dedication to translational investigations make me well-suited to successfully execute the proposed research.
One or more keywords matched the following items that are connected to Pitroda, Sean
Item TypeName
Concept Immunotherapy
Academic Article Integration of radiotherapy and immunotherapy for treatment of oligometastases.
Academic Article Tumor-reprogrammed resident T cells resist radiation to control tumors.
Academic Article Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.
Academic Article Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus.
Academic Article Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold.
Academic Article CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
Academic Article Prospective Evaluation of Stereotactic Body Radiotherapy and Immunotherapy for Mediastinal and Hilar Lymph Node Metastases.
Academic Article Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases.
Academic Article Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC.
Academic Article Radiotherapy and immunotherapy: open questions and future strategies.
Academic Article Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy.
Academic Article Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
Academic Article Tumor aneuploidy predicts survival following immunotherapy across multiple cancers.
Academic Article Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers.
Academic Article Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
Academic Article Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization.
Academic Article Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Academic Article Clinical and molecular correlates of tumor aneuploidy in metastatic non-small cell lung cancer.
Search Criteria
  • Immunotherapy